The FDA approved ribociclib, a CDK4/6 inhibitor, providing an additional treatment option for patients with early breast cancer at high risk for recurrence.

The phase 3 SONIA trial showed deferring CDK4/6 inhibitor treatment may not compromise HRQOL in patients with HR-positive/HER2-negative advanced breast cancer.

The FDA approved subcutaneous nivolumab for solid tumors, tiselizumab for advanced gastric and GEJ cancers, and key 2024 breast cancer breakthroughs are reviewed. Experts provide perspective on ...

Two other CDK4/6 inhibitors – Novartis' Kisqali (ribociclib) and Eli Lilly's Verzenios (abemaciclib) – have already been approved by NICE for both first- and second-line use in advanced HR+ ...

Kisqali (ribociclib) given alongside endocrine therapy as adjuvant therapy for patients with stage 2 or 3 hormone receptor-positive, HER2-negative breast cancer reduced patients’ risk for ...

Currently, there are three CDK4/6 inhibitors approved to treat breast cancer at different stages — Ibrance (chemical name: palbociclib), Kisqali (chemical name: ribociclib), and Verzenio (chemical ...

In 2023, the global breast cancer drug market is projected to be worth USD 10,733.1 million.  Between 2023 and 2033, the demand for breast cancer drugs is expected to expand at a CAGR of 1.1%, ...

A New York appellate court on Tuesday denied President-elect Donald Trump's bid to halt sentencing set for Friday for his conviction on criminal charges stemming from hush money paid to a porn ...

Ukraine's air force says one of its F-16 fighter jet pilots shot down six missiles during a Russian aerial attack last month. Meanwhile, Moscow says its troops have inflicted a series of defeats ...

Israel’s genocide in Gaza has put at least 114 hospitals and clinics out of service, yet nurses and doctors vow to continue providing care under the worst conditions imaginable. Fury at the ...

Jan. 7, 2025 — Researchers have devised a way to improve the accuracy of climate change models for the Global South by integrating historical records kept by ... Climate Extremes in 2024 ...